Mark Ringhoffer
Overview
Explore the profile of Mark Ringhoffer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
1496
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Dohner H, Weber D, Krzykalla J, Fiedler W, Wulf G, Salih H, et al.
Blood Adv
. 2022 Apr;
6(18):5345-5355.
PMID: 35486475
We conducted a single-arm, phase 2 trial (German-Austrian Acute Myeloid Leukemia Study Group [AMLSG] 16-10) to evaluate midostaurin with intensive chemotherapy followed by allogeneic hematopoietic-cell transplantation (HCT) and a 1-year...
12.
Tsamadou C, Engelhardt D, Platzbecker U, Sala E, Valerius T, Wagner-Drouet E, et al.
Front Immunol
. 2021 Dec;
12:771449.
PMID: 34970261
The loci are closely linked to the gene. Mismatches in these loci occur with a frequency of about 8%-12% in otherwise 10/10 HLA-matched transplant pairs. There is preliminary evidence that...
13.
Mytilineos D, Tsamadou C, Neuchel C, Platzbecker U, Bunjes D, Schub N, et al.
Front Immunol
. 2021 Feb;
11:614976.
PMID: 33569061
T-cell epitope matching according to the TCE3 algorithm classifies HLA-DPB1 mismatches in permissive and non-permissive. This classification has been shown to be predictive for mortality and acute GvHD (aGvHD) events...
14.
Gagelmann N, Eikema D, de Wreede L, Rambaldi A, Iacobelli S, Koster L, et al.
Bone Marrow Transplant
. 2020 Jul;
56(1):210-217.
PMID: 32710010
We analyzed newly diagnosed multiple myeloma patients with del(17p) and/or t(4;14) undergoing either upfront single autologous (auto), tandem autologous (auto-auto) or tandem autologous/reduced-intensity allogeneic (auto-allo) stem cell transplantation. 623 patients...
15.
Rucker F, Agrawal M, Corbacioglu A, Weber D, Kapp-Schwoerer S, Gaidzik V, et al.
Blood
. 2019 Sep;
134(19):1608-1618.
PMID: 31554635
We performed serial measurable residual disease (MRD) monitoring in bone marrow (BM) and peripheral blood (PB) samples of 155 intensively treated patients with RUNX1-RUNX1T1+ AML, using a qRT-PC-based assay with...
16.
Nguyen T, Scholl K, Idler I, Wais V, Korper S, Lotfi R, et al.
Leuk Lymphoma
. 2019 Sep;
61(2):481-484.
PMID: 31547738
No abstract available.
17.
Agrawal M, Schwarz P, Giaimo B, Bedzhov I, Corbacioglu A, Weber D, et al.
Leukemia
. 2019 Aug;
34(2):630-634.
PMID: 31462736
No abstract available.
18.
Schlenk R, Weber D, Fiedler W, Salih H, Wulf G, Salwender H, et al.
Blood
. 2018 Dec;
133(8):840-851.
PMID: 30563875
Patients with acute myeloid leukemia (AML) and a internal tandem duplication (ITD) have poor outcomes to current treatment. A phase 2 hypothesis-generating trial was conducted to determine whether the addition...
19.
Paschka P, Schlenk R, Weber D, Benner A, Bullinger L, Heuser M, et al.
Leukemia
. 2018 May;
32(7):1621-1630.
PMID: 29720733
In this phase Ib/IIa study (ClinicalTrials.gov Identifier: NCT00850382) of the German-Austrian AML Study Group (AMLSG) the multikinase inhibitor dasatinib was added to intensive induction and consolidation chemotherapy and administered as...
20.
Fuerst D, Neuchel C, Niederwieser D, Bunjes D, Gramatzki M, Wagner E, et al.
Blood
. 2016 Nov;
128(26):3169-3176.
PMID: 27811019
Major histocompatibility complex class I polypeptide-related sequence A (MICA) is a highly polymorphic ligand of the activating NKG2D receptor on natural killer (NK) cells, γδ-T cells, and NKT cells. MICA...